Clinical Trial Update: Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that the Phase 1/2 study of ARV-110 in metastatic castration-resistant prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ARV-110 (ARV-110)

Snippet

Sponsor: Arvinas Inc. | Conditions: Prostate Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED